A5075785739- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cardiac Imaging and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Radiation Therapy and Dosimetry
- Advanced X-ray and CT Imaging
- MRI in cancer diagnosis
- Lung Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Advances in Oncology and Radiotherapy
- Epigenetics and DNA Methylation
- Head and Neck Cancer Studies
Clatterbridge Cancer Centre NHS Foundation Trust
2015-2025
723 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1L maintenance therapy plus best supportive care (BSC) significantly improved overall survival (OS) and progression-free (PFS) vs BSC alone in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed platinum-based chemotherapy (PBC). UK, initial access to was provided via Early Access Medicines Scheme (EAMS) from September 2020. This study reports 24-month real-world outcomes treated...
Objective: Prostate dose painting radiotherapy requires the accurate identification of dominant intraprostatic lesions (DILs) to be used as boost volumes; these can identified on multiparametric MRI (mpMRI) or choline positron emission tomography (PET)/CT. Planning scans are usually performed after 2–3 months androgen deprivation therapy (ADT). We examine effect ADT tracer uptake and volumes PET/CT. Methods: Fluoroethylcholine (18F choline) PET/CT was for planning in patients with...
59 Background: Prostate dose painting (boosting intra-prostatic tumour volumes) may improve biochemical relapse-free survival similar to whole organ dose-escalation without the associated increased toxicity. We present a pre-defined secondary endpoint of 2 year outcome for patients at one two UK centres in phase II trial (BIOPROP20) on dose-painting radiotherapy intermediate high risk treated with 60Gy/20# and concurrent 68Gy boost. Methods: Pinnacle software was used VMAT planning boost...